The takeover is just the next step.
There is overlap between Healius and Vision Eye institute in day surgeries and synergies.
I suspect after Healius. Jangho will go after MVF next as IVF uses a bit of diagnostics such as ultrasounds and other genetics tests.
I think Jangho has a clear strategy in healthcare sector in Australia. Not to mention it provides a way to consolidate healthcare in China.
Imagine your a chinese doctor who will be given an opportunity to migrate to australia after years of loyal service in China.
Ann: Non-binding indicative proposal for acquisition of Healius, page-32
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add HLS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.41 |
Change
-0.015(1.06%) |
Mkt cap ! $1.212B | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.45 | $1.39 | $1.453M | 1.034M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 16317 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.41 | 14045 | 2 |
View Market Depth
| Last trade - 16.10pm 27/11/2024 (20 minute delay) ? |
| HLS (ASX) Chart |
